10,659 XNAS Volume
XNAS 19 Mar, 2025 1:27 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Katharine Peterson | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 31,900 | 31,900 | - | - | Stock Option (Right to Buy) | |
| Eric Devroe | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 140,540 | 140,540 | - | - | Stock Option (Right to Buy) | |
| Erick Gamelin | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 78,078 | 78,078 | - | - | Stock Option (Right to Buy) | |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 109,309 | 109,309 | - | - | Stock Option (Right to Buy) | |
| Peter Blume-Jensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 390,390 | 390,390 | - | - | Stock Option (Right to Buy) | |
| Peter Blume-Jensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 140,540 | 140,540 | - | - | Stock Option (Right to Buy) | |
| Jean-Marie Cuillerot | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 78,078 | 78,078 | - | - | Stock Option (Right to Buy) | |
| Peter Blume-Jensen | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.54 per share. | 21 Feb 2025 | 19,904 | 2,285,781 | - | 5.5 | 110,268 | Common Stock |
| Katharine Peterson | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 14 Feb 2025 | 116 | 4,419 | - | 5.4 | 629 | Common Stock |
| Peter Blume-Jensen | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 14 Feb 2025 | 37,152 | 2,305,685 | - | 5.4 | 201,364 | Common Stock |
| Peter Blume-Jensen | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 14 Feb 2025 | 579 | 316,177 | - | 5.4 | 3,138 | Common Stock |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 14 Feb 2025 | 434 | 26,088 | - | 5.4 | 2,352 | Common Stock |
| Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 14 Feb 2025 | 469 | 16,492 | - | 5.4 | 2,542 | Common Stock |
| Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 14 Feb 2025 | 724 | 67,147 | - | 5.4 | 3,924 | Common Stock |
| Peter Blume-Jensen | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.44 per share. | 21 Nov 2024 | 19,910 | 2,342,837 | - | 6.4 | 128,220 | Common Stock |
| Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.92 per share. | 14 Nov 2024 | 402 | 16,961 | - | 7.9 | 3,184 | Common Stock |
| Peter Blume-Jensen | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.92 per share. | 14 Nov 2024 | 59,766 | 2,362,747 | - | 7.9 | 473,347 | Common Stock |
| Peter Blume-Jensen | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.92 per share. | 14 Nov 2024 | 490 | 316,756 | - | 7.9 | 3,881 | Common Stock |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.92 per share. | 14 Nov 2024 | 368 | 26,522 | - | 7.9 | 2,915 | Common Stock |
| Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.92 per share. | 14 Nov 2024 | 613 | 67,871 | - | 7.9 | 4,855 | Common Stock |
| Katharine Peterson | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.92 per share. | 14 Nov 2024 | 99 | 4,535 | - | 7.9 | 784 | Common Stock |
| Peter Blume-Jensen | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.19 per share. | 21 Aug 2024 | 79,616 | 2,422,513 | - | 9.2 | 731,671 | Common Stock |
| Peter Blume-Jensen | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 59,765 | 2,502,129 | - | 7.0 | 419,550 | Common Stock |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 368 | 26,890 | - | 7.0 | 2,583 | Common Stock |
| Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 402 | 17,363 | - | 7.0 | 2,822 | Common Stock |
| Kristina Masson | Director, EVP - Business Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 490 | 317,246 | - | 7.0 | 3,440 | Common Stock |
| Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 613 | 68,484 | - | 7.0 | 4,303 | Common Stock |
| Katharine Peterson | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 99 | 4,634 | - | 7.0 | 695 | Common Stock |
| Derek DiRocco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,275 | 20,275 | - | - | Stock Option (Right to Buy) | |
| Sharon Shacham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,275 | 20,275 | - | - | Stock Option (Right to Buy) | |
| Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,275 | 20,275 | - | - | Stock Option (Right to Buy) | |
| Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,275 | 20,275 | - | - | Stock Option (Right to Buy) | |
| Eric Devroe | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 10,000 | 86,615 | - | - | Stock Option (Right to Buy) | |
| Eric Devroe | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. | 17 May 2024 | 10,000 | 69,097 | - | 1.0 | 10,400 | Common Stock |
| Katharine Peterson | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 99 | 4,733 | - | 8.4 | 828 | Common Stock |
| Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 613 | 59,097 | - | 8.4 | 5,125 | Common Stock |
| Kristina Masson | Director, EVP - Business Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 490 | 317,736 | - | 8.4 | 4,096 | Common Stock |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 368 | 27,258 | - | 8.4 | 3,076 | Common Stock |
| Peter Blume-Jensen | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 54,918 | 2,561,894 | - | 8.4 | 459,114 | Common Stock |
| Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 402 | 17,765 | - | 8.4 | 3,361 | Common Stock |
| Santhosh Palani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Gamelin Erick | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 45,045 | 45,045 | - | - | Stock Option (Right to Buy) | |
| Devroe Eric | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 90,090 | 90,090 | - | - | Stock Option (Right to Buy) | |
| Blume-Jensen Peter | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 90,090 | 90,090 | - | - | Stock Option (Right to Buy) | |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 90,090 | 90,090 | - | - | Stock Option (Right to Buy) | |
| Peter Blume-Jensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 225,226 | 225,226 | - | - | Stock Option (Right to Buy) | |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 14 Feb 2024 | 434 | 27,626 | - | 3.4 | 1,476 | Common Stock |
| Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 14 Feb 2024 | 468 | 18,167 | - | 3.4 | 1,591 | Common Stock |
| Blume-Jensen Peter | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 14 Feb 2024 | 41,861 | 2,616,812 | - | 3.4 | 142,327 | Common Stock |
| Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 14 Feb 2024 | 723 | 59,710 | - | 3.4 | 2,458 | Common Stock |
| Masson Kristina | Director, EVP - Business Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 14 Feb 2024 | 579 | 318,226 | - | 3.4 | 1,969 | Common Stock |
| Jean-Marie Cuillerot | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2024 | 99,300 | 99,300 | - | - | Stock Option (Right to Buy) | |
| Peter Blume-Jensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2023 | 493,994 | 2,897,696 | - | 0 | Common Stock | |
| Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 9,500 | 183,119 | - | - | Stock Option (Right to Buy) | |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.63 per share. | 16 Jun 2023 | 9,500 | 29,530 | - | 3.6 | 34,485 | Common Stock |
| Eric Devroe | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2023 | 9,225 | 96,615 | - | - | Stock Option (Right to Buy) | |
| Eric Devroe | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. | 05 Jun 2023 | 9,225 | 62,883 | - | 1.0 | 9,594 | Common Stock |
| Peter Blume-Jensen | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 31 May 2023 | 33,605 | 2,403,702 | - | 3.9 | 130,387 | Common Stock |
| Peter Blume-Jensen | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2023 | 33,605 | 90,855 | - | - | Stock Option (Right to Buy) | |
| Sharon Shacham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 35,235 | 35,235 | - | - | Stock Option (Right to Buy) | |
| Derek DiRocco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 35,235 | 35,235 | - | - | Stock Option (Right to Buy) | |
| Peter Blume-Jensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 503,419 | 2,310,007 | - | 0 | Common Stock | |
| Peter Blume-Jensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 934,731 | 1,806,588 | - | 0 | Common Stock | |
| Peter Blume-Jensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 60,090 | 2,370,097 | - | 0 | Common Stock | |
| Peter Blume-Jensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 26,707 | 320,705 | - | 0 | Common Stock | |
| Peter Blume-Jensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 180,269 | 180,269 | - | - | Stock Option (Right to Buy) | |
| Peter Blume-Jensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 80,120 | 80,120 | - | - | Stock Option (Right to Buy) | |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 60,090 | 60,090 | - | - | Stock Option (Right to Buy) | |
| Rasmus Holm-Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 20,030 | 20,030 | - | 0 | Common Stock | |
| Erick Gamelin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 20,030 | 20,030 | - | 0 | Common Stock | |
| Erick Gamelin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 60,090 | 60,090 | - | - | Stock Option (Right to Buy) | |
| Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 26,707 | 320,705 | - | 0 | Common Stock | |
| Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 934,731 | 1,806,588 | - | 0 | Common Stock | |
| Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 503,419 | 2,310,007 | - | 0 | Common Stock | |
| Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 80,120 | 80,120 | - | - | Stock Option (Right to Buy) | |
| Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 180,269 | 180,269 | - | - | Stock Option (Right to Buy) | |
| Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 60,090 | 2,370,097 | - | 0 | Common Stock | |
| Eric Devroe | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 33,383 | 53,658 | - | 0 | Common Stock | |
| Eric Devroe | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 100,150 | 100,150 | - | - | Stock Option (Right to Buy) | |
| Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 35,235 | 35,235 | - | - | Stock Option (Right to Buy) |